San Jose, California, Feb. 24, 2023 (GLOBE NEWSWIRE) -- Yasheng's AI-Powered Cancer Therapy Patent Revolutionizes Immunotherapy Development SAN JOSE, CA--(February...
– Initiated enrollment in Phase 1B clinical trial of SL-172154 in combination with mirvetuximab soravtansine in platinum-resistant ovarian cancer –...
Nes-Ziona, Israel, Feb. 23, 2023 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy...
SOUTH SAN FRANCISCO, Calif., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB) today announced that the Compensation Committee...
WALTHAM, Mass., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology...
BOSTON, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of...
Infectimune™ (R-DOTAP) nanoparticles significantly enhance cytokine-inducing, CD4 T cell responses compared to leading commercial adjuvants being used in approved vaccinesFLORHAM...
SOUTH SAN FRANCISCO, Calif., Feb. 16, 2023 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage...
NEW YORK, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP, “Indaptus” or “the Company”), a biotechnology company...
-- NCI will lead the Phase 1 study using Gritstone’s proprietary “off the shelf” vaccine technology for mutant KRAS solid...
NEW YORK and VIENNA, Austria, Feb. 13, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing...
The poster presents data for 42 patients with relapsed or refractory multiple myeloma who were treated with NXC-201 (formerly HBI0101),...
SAN FRANCISCO and BERLIN, Feb. 08, 2023 (GLOBE NEWSWIRE) -- T-knife Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to developing...
New Agreement Enhances High-Parameter Panels on Cytek Cell Analysis SystemsFREMONT, Calif., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Delivering a boost...
NEW YORK, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP, “Indaptus” or “the Company”), a biotechnology company...
Abstract, titled “HPV16-specific CD4 and CD8 T cell activation and functionality in patients receiving combination PDS0101 immunotherapy,” highlights data generated...
Media Release 20 patients with 1st line non-small cell lung cancer (1L NSCLC) now enrolled in the first triple combination...
BOSTON, Feb. 06, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company focused on the discovery and...
ALK (ALKB:DC / OMX: ALK B / AKBLF) today announced that its Biologics License Application (BLA) for...
ALK's (ALKB:DC / OMX: ALK B / AKBLF) Board of Directors has approved the company’s 2022 annual report (ESEF-version ALK-2022-12-31-en...